Overview

* Clene ( CLNN ) reports Q3 net loss of $8.8 mln, increased from $8.0 mln last year

* Cash and cash equivalents total $7.9 mln, runway extended into Q2 2026

* Company plans NDA submission for CNM-Au8 in Q1 2026 under accelerated approval

Outlook

* Clene plans to submit NDA for ALS treatment in Q1 2026

* Company expects first patient dosed in Phase 3 ALS trial in H1 2026

* Clene extends cash runway into Q2 2026

Result Drivers

* Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$8.78

Income mln

Q3 Basic -$0.85

EPS

Q3 -$5.65

Income mln

From

Operatio

ns

Q3 $5.66

Operatin mln

g

Expenses

Q3 -$8.78

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Clene Inc ( CLNN ) is $30.00, about 68.6% above its November 12 closing price of $9.41

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)